VolitionRx Limited to Attend Multiple Conferences in September
Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers
VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update
VolitionRx Limited Schedules Second Quarter 2017 Earnings Conference Call and Business Update
VolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute
Volition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Institute
Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress
VolitionRx Limited Corrects an Earlier Announcement
VolitionRx Limited to Present at Multiple Investor Conferences in June
A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays
